Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 18.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 18.0 Contact Hours.
To earn an additional 4.0 AMA PRA Category 1 Credits™, attend the CAR T Preconference Workshop.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 18.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Accreditation/Designation of Credit for Nursing Track (Clinical Pearls for Practice Educational Session and Networking for Advanced Practitioners)
This activity is approved for 1.75 contact hour(s) of continuing education (which includes 1.75 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 19023560. This activity was planned in accordance with AANP Accreditation Standards and Policies.
Acknowledgement of Commercial Support
This activity is supported by educational grants from AbbVie Inc., Acerta Pharma – A member of the AstraZeneca Group, Adaptive Biotechnologies, Celgene Corporation, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Jazz Pharmaceuticals, Inc., NewLink Genetics, Novartis Pharmaceuticals Corporation, Rigel Pharmaceuticals, Inc., Seattle Genetics, Inc., and Takeda Oncology.
23rd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma
CAR T Preconference Workshop at the PER Winter Hematology® Meeting
Thursday, February 28, 2019
2:00 PM – 5:30 PM
Eden Roc Miami Beach
4525 Collins Avenue
Miami Beach, FL 33140
Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The development of chimeric antigen receptor (CAR) T-cell therapy has provided new treatment options for patients with relapsed hematologic malignancies, with ongoing research in leukemias, lymphomas, and myeloma. This workshop on CAR T-cell therapies will help you become familiar with applications of CAR T cells in patients with leukemias, as well as how durable responses are achieved with CAR T-cell therapy in patients with lymphomas. Real-world data will be discussed, which also show similar durability to that seen in clinical trials. In addition, the expert faculty will provide you with important aspects of managing treatment-related adverse events and how these are manifested in the different diseases. Finally, you will learn about future developments in CAR T-cell therapy, including the potential for predictive biomarkers and the application of this modality in solid tumors.
Benefits of attending the CAR T Preconference Workshop:
- Gain knowledge of the distinct mechanism of action of CAR T-cell therapy
- Expand knowledge of unique properties of CAR T cells compared with conventional systemic therapies
- Improve knowledge and competence in the application of CAR T cells in patients with relapsed hematologic malignancies
- Learn about managing treatment-related adverse events with CAR T cells
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
This educational activity is directed toward community-based hematologists and medical oncologists, as well as fellows involved in the treatment and management of patients with hematologic malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of hematologic malignancies may also participate.
|Thursday, February 28, 2019|
|2:00 PM – 2:10 PM||Welcome and Introductions||Andre H. Goy, MD, MS|
|2:10 PM||Case/Audience Response System (ARS)|
|2:15 PM||What's New With CAR T Cells in Leukemias||Jae H. Park, MD|
|2:30 PM||Question & Answer Session|
|2:40 PM||Update on CAR T Cells in Lymphoma||Loretta J. Nastoupil, MD|
|02:55 PM||Question & Answer Session|
|03:00 PM||The Emergence of CAR T Cells in Myeloma||Noopur Raje, MD|
|03:55 PM||What's Next for CAR T Cells||Frederick L. Locke, MD|
|04:10 PM||Question & Answer Session|
|4:20 PM||CAR T Cells in Solid Tumors||Denis Migliorini, MD|
|4:35 PM||Question & Answer Session|
|4:45 PM||How to Predict Response and Overcome Resistance to CAR T-Cell Therapy||Joseph A. Fraietta, PhD|
|5:00 PM||Question & Answer Session|
|5:05 PM||Interactive Panel Discussion and Medical Crossfire®||Joseph A. Fraietta, PhD|
|5:30 PM – 6:30 PM||Networking Reception|
Andre H. Goy, MD, MS
Chairman and Executive Director
Lymphoma Division Chief, John Theurer Cancer Center
Chief Science Officer, RCCA
Lydia Pfund Chair for Lymphoma
Professor of Medicine, Georgetown University